Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Sinolpan is an over‑the‑counter, plant‑derived respiratory medicine based on **cineole**, a monoterpene oxide purified from eucalyptus oil, formulated as gastro‑resistant soft capsules for systemic delivery in the intestine.[1][3][4][5][7][9] It is marketed by Engelhard Arzneimittel for the symptomatic treatment of bronchitis, colds, and acute or chronic inflammatory diseases of the upper and lower respiratory tract such as rhinosinusitis and sinusitis, where it acts as an expectorant and anti‑inflammatory agent that liquefies and mobilizes viscous mucus, facilitates mucociliary clearance, decongests the nasal passages, and reduces pressure sensations in the head.[1][3][5][7][9] By modulating mucus production and exerting anti‑inflammatory effects on the airway mucosa, Sinolpan improves breathing comfort and quality of life in adults and children when used as adjunctive therapy in respiratory infections.[1][3][5][6][8][9]
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Sinolpan.